Jakarta, March 28, 2024. Based on the Consolidated Financial Statements of PT Enseval Putera Megatrading Tbk and its Subsidiaries (the Company) as of December 31, 2023, and for the period then ended (Audited), the Company hereby informs that at the end of 2023, the Company's Net Sales were recorded at IDR 28,507.87 billion, representing a 1.71% increase compared to Net Sales at the end of 2022.

Meanwhile, the Company's Profit for the Period was recorded at IDR 688.37 billion, a decrease of 18.30% compared to IDR 842.59 billion for the same period in 2022. This is due to the dynamic economic and market conditions. The Company believes that the healthcare industry will continue to grow in the long term, despite the challenges.

The Company's Net Sales growth was supported by the performance of each division, consisting of the Consumer Goods Division, Prescription Drugs, Over-the-Counter Drugs, Raw Materials for Sale, Medical Equipment, Veterinary and Livestock Drugs, and Healthcare and Transportation Services.

The details of the performance of each of the Company's divisions are as follows:

The Consumer Goods Division contributed the largest to total Net Sales, accounting for 41.63%. At the end of 2023, this division recorded Net Sales of IDR 11,866.90 billion, an increase of 3.92% compared to the same period in 2022.

The Prescription Drugs Division contributed the second-largest revenue after the Consumer Goods Division, accounting for 32.25%. By the end of 2023, the Prescription Drugs Division recorded Net Sales of Rp9,194.65 billion, representing a 9.28% increase compared to the same period in 2022.

The Over-the-Counter Drugs Division recorded Net Sales of Rp3,558.40 billion at the end of 2023, contributing 12.48% of the total revenue, a 14.11% decrease compared to the same period in 2022.

The Raw Materials for Sale Division recorded Net Sales of Rp2,237.28 billion at the end of 2023, representing a 10.67% decrease compared to the same period in 2022, contributing 7.85%.

The Medical Devices Division contributed 5.28% of the Company's revenue at the end of 2023, with Net Sales of Rp1,506.21 billion, a 4.72% increase compared to the same period in 2022.

Net Sales from the Animal and Livestock Medicine Division were recorded at Rp51.22 billion, a 6.21% increase compared to the same period in 2022. The Animal and Livestock Medicine Division contributed 0.18% to the Company's total Net Sales.

Net Sales from the Healthcare Services and Transportation Division were recorded at Rp93.22 billion, a 53.92% increase compared to the same period in 2022. The Healthcare Services and Transportation Division contributed 0.33% to the Company's total Net Sales.

About Enseval

Enseval is the largest distribution company in Indonesia, having started distribution activities in 1973 and currently employs more than 4,700 employees. Enseval became a public company on August 1, 1994, under the name PT Enseval Putera Megatrading Tbk (IDX: EPMT). In addition to distributing products from the Kalbe Group, Enseval has also been trusted by other principals both domestically and internationally. The Company has an extensive distribution network with 3 Distribution Centers located in Jakarta, Cikarang, and Surabaya and 48 branches spread throughout the Indonesian Archipelago and 24 branches through its subsidiary, PT Tri Sapta Jaya. To date, the Company has 9 subsidiaries operating in the fields of distribution, raw materials, medical equipment, health care services, and transportation.